Potential use of folate-appended methyl-β-cyclodextrin as an anticancer agent

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Onodera, Risako ^a   Motoyama, Keiichi ^a   Okamatsu, Ayaka ^a   Higashi, Taishi ^a   Arima, Hidetoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; CASPASE 3; CASPASE 7; CHOLESTEROL; DOXORUBICIN; DRUG DERIVATIVE; FOLIC ACID; METHYL BETA CYCLODEXTRIN; METHYL-BETA-CYCLODEXTRIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL STRAIN KB; COLON TUMOR; DRUG EFFECT; DRUG SCREENING; HEMOLYSIS; HUMAN; MALE; METABOLISM; MOUSE; RABBIT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CHOLESTEROL; COLONIC NEOPLASMS; DOXORUBICIN; FOLIC ACID; HEMOLYSIS; HUMANS; KB CELLS; MALE; MICE; MICE, INBRED BALB C; RABBITS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873133493     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01104     Document Type: Article

References (53)

1. Wong, H. L., Bendayan, R., Rauth, A. M., Li, Y. & Wu, X. Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59, 491-504 (2007). (Pubitemid 47259227)
2. Harata, M. et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 104, 1442-1449 (2004). (Pubitemid 39166523)
3. Lukyanov, A. N., Elbayoumi, T. A., Chakilam, A. R. & Torchilin, V. P. Tumortargeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Control. Release 100, 135-144 (2004). (Pubitemid 39445991)
4. Park, J. W. et al. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release 74, 95-113 (2001). (Pubitemid 32727613)
5. Pastorino, F. et al. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 63, 86-92 (2003). (Pubitemid 36070424)
6. Roche, A. C. et al. Glycofection: facilitated gene transfer by cationic glycopolymers. Cell Mol. Life Sci. 60, 288-297 (2003). (Pubitemid 36343909)
7. Chen, H., Ahn, R., Van den Bossche, J., Thompson, D. H. & O'Halloran, T. V. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol. Cancer Ther. 8, 1955-1963 (2009).
8. Gabizon, A. et al. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother. Pharmacol. 66, 43-52 (2010).
9. Lu, Y. & Low, P. S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54, 675-693 (2002). (Pubitemid 35247522)
10. Mi, Y., Liu, Y.&Feng, S. S. Formulation of Docetaxel by folic acid-conjugated d-atocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials 32, 4058-4066 (2011).
11. Nukolova, N. V., Oberoi, H. S., Cohen, S. M., Kabanov, A. V. & Bronich, T. K. Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials 32, 5417-5426 (2011).
12. Hayakawa, K. et al. Sensitivity to apoptosis signal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in in vivo adult cardiac cells. Circulation 105, 3039-3045 (2002). (Pubitemid 34693839)
13. Kobayashi, T. et al. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 329, 94-102 (2007). (Pubitemid 44937528)
14. Miyajima, Y. et al. Transferrin-loaded nido-carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy. Bioconjug. Chem. 17, 1314-1320 (2006). (Pubitemid 44455341)
15. Kim, I. Y. et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J. Control. Release 140, 55-60 (2009).
16. Mamot, C. et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res. 63, 3154-3161 (2003). (Pubitemid 36735867)
17. Schiffelers, R. M. et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 91, 115-122 (2003). (Pubitemid 37288882)
18. Low, P. S. & Kularatne, S. A. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol. 13, 256-262 (2009).
19. Antony, A. C. The biological chemistry of folate receptors. Blood 79, 2807-2820 (1992).
20. Limmon, G. V. et al. Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA. FASEB J. 22, 159-167 (2008).
21. Parker, N. et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338, 284-293 (2005). (Pubitemid 40312593)
22. Ross, J. F., Chaudhuri, P. K.&Ratnam,M.Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73, 2432-2443 (1994). (Pubitemid 24129130)
23. Toffoli, G. et al.Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 74, 193-198 (1997). (Pubitemid 27234510)
24. Low, P. S., Henne, W. A. & Doorneweerd, D. D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 41, 120-129 (2008).
25. Szente, L. & Szejtli, J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 36, 17-28 (1999). (Pubitemid 29074474)
26. Uekama, K. & Otagiri, M. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 3, 1-40 (1987). (Pubitemid 17231927)
27. Motoyama, K. et al. Effect of 2,6-di-O-methyl-a-cyclodextrin on hemolysis and morphological change in rabbit's red blood cells. Eur. J. Pharm. Sci. 29, 111-119 (2006). (Pubitemid 44332884)
28. Motoyama, K. et al. Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated b-cyclodextrins. Biol. Pharm. Bull. 32, 700-705 (2009).
29. Ohtani, Y., Irie, T., Uekama, K., Fukunaga, K. & Pitha, J. Differential effects of a-, b-and c-cyclodextrins on human erythrocytes. Eur. J. Biochem. 186, 17-22 (1989). (Pubitemid 20015121)
30. Galbiati, F., Razani, B.&Lisanti, M. P. Emerging themes in lipid rafts and caveolae. Cell 106, 403-411 (2001). (Pubitemid 32786984)
31. Simons, K. & Ehehalt, R. Cholesterol, lipid rafts, and disease. J. Clin. Invest. 110, 597-603 (2002). (Pubitemid 34988781)
32. Anderson, R. G. & Jacobson, K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 296, 1821-1825 (2002). (Pubitemid 34596260)
33. Motoyama, K. et al. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-b-cyclodextrin, not 2,6-di-O-methyl-a-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells. Eur. J. Pharm. Sci. 38, 249-261 (2009).
34. Grosse, P. Y., Bressolle, F. & Pinguet, F. Antiproliferative effect of methylb-cyclodextrin in vitro and in human tumour xenografted athymic nude mice. Br. J. Cancer 78, 1165-1169 (1998). (Pubitemid 28479145)
35. Loftsson, T. & Brewster, M. E. Pharmaceutical applications of cyclodextrins: basic science and product development. J. Pharm. Pharmacol. 62, 1607-1621 (2010).
36. Onodera, R., Motoyama, K. & Arima, H. Design and Evaluation of Folateappended Methyl-b-cyclodextrin as a New Antitumor Agent. J. Incl. Phenom. Macrocycl. Chem. 70, 321-326 (2011).
37. Le Roy, C. & Wrana, J. L. Clathrin-and non-clathrin-mediated endocytic regulation of cell signalling. Nat. Rev. Mol. Cell Biol. 6, 112-126 (2005). (Pubitemid 40215807)
38. Doherty, G. J. & McMahon, H. T. Mechanisms of endocytosis. Annu. Rev. Biochem. 78, 857-902 (2009).
39. Kelemen, L. E. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int. J. Cancer 119, 243-250 (2006).
40. Dhar, S., Liu, Z., Thomale, J., Dai, H. & Lippard, S. J. Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J. Am. Chem. Soc. 130, 11467-11476 (2008).
41. Guaragna, A. et al. Synthesis and evaluation of folate-based chlorambucil delivery systems for tumor-targeted chemotherapy. Bioconjug. Chem. 23, 84-96 (2012).
42. Long, J. S. & Ryan, K. M. New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene (2012).
43. Tan, M. L., Ooi, J. P., Ismail, N.,Moad, A. I. &Muhammad, T. S. Programmed cell death pathways and current antitumor targets. Pharm. Res. 26, 1547-1560 (2009).
44. Park, E. K. et al. Cholesterol depletion induces anoikis-like apoptosis via FAK down-regulation and caveolae internalization. J. Pathol. 218, 337-349 (2009).
45. Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 95, 4607-4612 (1998). (Pubitemid 28207960)
46. Nagy, J. A., Dvorak, A. M. & Dvorak, H. F. VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2, 251-275 (2007). (Pubitemid 46448066)
47. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
48. Nagy, J. A., Chang, S. H., Dvorak, A. M. & Dvorak, H. F. Why are tumour blood vessels abnormal and why is it important to know? Br. J. Cancer 100, 865-869 (2009).
49. Chauhan, V. P., Stylianopoulos, T., Boucher, Y. & Jain, R. K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281-298 (2011).
50. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
51. Chauhan, V. P. et al.Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7, 383-388 (2012).
52. Hamasaki, K., Kogure, K. & Ohwada, K. A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt. Toxicon. 34, 490-495 (1996). (Pubitemid 26130128)
53. Ono, N., Arima, H., Hirayama, F. & Uekama, K. A moderate interaction of maltosyl-a-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin. Biol. Pharm. Bull. 24, 395-402 (2001). (Pubitemid 32377608)